Pearson has the most well-validated and wide-ranging test offering for use in clinical trials and research. Our reliable, valid and sensitive tools can provide pharmaceutical companies, biotech companies and contract research organizations the critical information and data needed to assess the efficacy and safety relating to a medication, devices or other intervention.
Our test offerings assess a broad range of factors and measure change in a variety of areas and symptoms including:
Anxiety
Attention Deficit Disorder
Cognitive Functioning
Depression
Dementia/Alzheimer’s |
Executive Functioning
Fluency (Stuttering)
Memory
Mild Cognitive Impairment |
Read on for more information about our test offerings, translations and how to apply for a license to include our tests in your next clinical trial.
Frequently used tests in clinical trials & research
The BAI is the most widely used instrument for detecting anxiety. Aligned with the DSM-IV, BAI provides a criteria-referenced self-report that is clinically sensitive and takes only five minutes to complete.
The BDI-II is the most widely used instrument for detecting depression. Aligned with the DSM-IV, BDI-II provides a criteria-referenced self-report that is clinically sensitive and takes only five minutes to complete.
The BSI helps assess and monitor key outcomes in psychological distress in nine areas including depression, anxiety, hostility, paranoid ideation and psychoticism. It also provides a measure of overall level of psychological distress and is ideal for progress monitoring.
The BSI 18 test measures psychological distress in three areas – depression, anxiety and somatization and includes an overall measure of distress. It can be given multiple times to measure change in symptomology.
The BCSE is designed to quick assess a patients overall cognitive status. It covers Orientation, Time, Mental Control, Planning and Visual-perceptual processing, Incidental Recall, Inhibitory Control, and Verbal Productivity. It’s applicable for use with patients suspected of dementia, mild MR, or Alzheimer’s disease. The BCSE yields a performance classification focused on impaired rather than normal or superior performance.
Available for children three years of age to adults, the Brown ADD Scales go beyond measures that only address hyperactivity to help assess for less apparent impairments of executive functioning.
The mostly widely used battery for Executive Function, D-KEFS includes nine stand-alone tests to measure multiple aspects of executive function. Frequently used tests from this battery for research purposes include:
- Trails Making : To assess flexibility of thinking on a visual-motor task
- Verbal Fluency: To assess fluent productivity in the verbal domain
- Design Fluency: To assess fluent productivity in the spatial domain.
The first and only standardized and commercialized self-report measure that examines the entirety of the stuttering disorder from the perspective of an individual who stutters. The OASES instrument evaluates the speaker’s perceptions of observable stuttering behaviors, reactions to stuttering, and difficulties in performing daily activities involving communication.
The SCL-90-R helps assess and monitor key outcomes in psychological distress in nine areas including depression, anxiety, hostility, paranoid ideation and psychoticism. It also provides a measure of overall level of psychological distress and is ideal for progress monitoring.
RBANS is a brief, individually administered battery to assess Immediate/Delayed Memory, Visuospatial/Constructional, Attention, and Language domains. RBANS can be administered multiple times using the four parallel forms available in more than 25 languages.
This market leading scale of adult memory has been recently revised. WMS-IV consists of multiple subtests that yield Immediate and Delayed Index Scores for Auditory and Visual Memory as well as Visual Working Memory. There is also an Older Adult (briefer) version.
This test measures the ability to learn and retain novel visual – visual associations which is particularly useful in examinees with low language functioning. The examinee learns to associate a series of colors and designs over a series of learning trials. After a long-delay (30 minutes), the examinee must recall which design was associated with a specific color in the previous learning trials.
The test measures the ability to learn and retain novel word associations. The examinee learns to associate a list of related and unrelated words over a series of learning trials. After a long-delay (30 minutes), the examinee is asked to recall which word was associated with the target word on the learning trials.
The test measures verbal memory span and working memory. The examinee hears a series of digits of increasing length and must repeat them verbatim. In subsequent trials, the examinee hears a series of digits of increasing length and must repeat the digits in reverse order.
TFLS provides an ecologically valid, performance-based screening tool to identify level of care for individuals. It has been used in dementia and Alzheimer’s drug trials to monitor everyday behavior over time.
For a complete list of tests available from Pearson, click here.
Apply for a license agreement
Complete a permission request if you would like to obtain authorization to use a test in a clinical trial and the project involves utilizing the test in a different manner than our standard catalog offering (i.e.: inclusion in an ACASI system, CRF, translations). All requests are subject to approval and costs vary. Translations
Many of our tests have been translated into multiple languages. Such translations are available for use in research and clinical trials through our licensing process (discussed above). Should a translation not be available when you submit a permission request, our IP Permissions group will process as a request to translate. Other sources of information
Find trials for a specific medical condition or other criteria in the ClinicalTrials.gov registry. This information can be found at: www.clinicaltrials.gov/ct2/search